Biological agents reduce cardiovascular events in rheumatoid arthritis non-responsive to tumor necrosis factor-inhibitors – a national cohort study

Publication date: Available online 15 January 2020Source: Canadian Journal of CardiologyAuthor(s): Ming-Jer Hsieh, Cheng-Hung Lee, Ming-Lung Tsai, Chang-Fu Kao, Wen-Ching Lan, Yu-Tung Huang, Wen-Yi Tseng, Ming-Shien Wen, Shang-Hung ChangAbstractBackgroundTumor necrosis factor inhibitors (TNFi) improve joints outcomes and reduce cardiovascular (CV) risk in patients with rheumatoid arthritis (RA). However, 20-45% of RA patients are TNFi poor responders and have a significantly higher risk of CV events. In these TNFi non-responders, the use of second-line biological agents to improve synovial outcomes is supported by clinical trials and real-world experience. However, it remains unknown what kind of immune-mediated agent has the best CV prevention effect on this high-risk population.MethodsA nationwide RA cohort obtained from Taiwan’s National Health Insurance claims database was constructed. RA patients first treated with TNFi who then received either rituximab, tocilizumab or abatacept, were enrolled and followed for 2 years.ResultsA total of 89,973 RA patients were screened and 1,584 patients were ultimately included. The incidence of major adverse cardiac events (MACEs) at 2 years in the rituximab, tocilizumab and abatacept groups was 7.17%, 2.75% and 2.38%, respectively. Multivariate adjusted-Cox analysis showed tocilizumab had significantly lower risk than rituximab in myocardial infarction [Hazard Ratio (HR)=0.12; 95% Confidence Interval (CI): 0.02-0.56, p=0.008], a...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research

Related Links:

In this study, we investigated the link between AF and senescence markers through the assessment of protein expression in the tissue lysates of human appendages from patients in AF, including paroxysmal (PAF) or permanent AF (PmAF), and in sinus rhythm (SR). The major findings of the study indicated that the progression of AF is strongly related to the human atrial senescence burden as determined by p53 and p16 expression. The stepwise increase of senescence (p53, p16), prothrombotic (TF), and proremodeling (MMP-9) markers observed in the right atrial appendages of patients in SR, PAF, and PmAF points toward multiple inter...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In conclusion, in the Framingham Heart Study population, in the last 30 years, disease duration in persons with dementia has decreased. However, age-adjusted mortality risk has slightly decreased after 1977-1983. Consequences of such trends on dementia prevalence should be investigated. Recent Research on the Benefits of Exercise in Later Life https://www.fightaging.org/archives/2018/04/recent-research-on-the-benefits-of-exercise-in-later-life/ A sizable body of work points to the ability of older individuals to continue to obtain benefits through regular physical activity, and particularly in the case ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In conclusion, the present study demonstrated that TIGIT is a prominent negative immune regulator involved in immunosenescence. This novel finding is highly significant, as targeting TIGIT might be an effective strategy to improve the immune response and decrease age-related comorbidities. Delivery of Extracellular Vesicles as a Potential Basis for Therapies https://www.fightaging.org/archives/2018/01/delivery-of-extracellular-vesicles-as-a-potential-basis-for-therapies/ Here I'll point out a readable open access review paper on the potential use of extracellular vesicles as a basis for therapy: harveste...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche....
Source: Al Sears, MD Natural Remedies - Category: Complementary Medicine Authors: Tags: Anti-Aging Source Type: news
Abstract AbstractSeveral studies have pointed out a significant association between rheumatoid arthritis (RA) and accelerated atherosclerosis. At the best of our knowledge, no such study has been carried out in a large Italian series and, in this study, we aimed to investigate the prevalence of both subclinical atherosclerosis and history of cardiovascular events (CVEs), in patients consecutively admitted from January 1, 2015 to December 31, 2015 to Rheumatology Units throughout the whole Italy.Centers members of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) were invited to enrol patients conse...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Actemra, manufactured by Roche/Genentech, has been associated with heart attack, heart failure, stroke, pancreatitis, lung disease, gastrointestinal perforation, and more
Source: Disabled World - Category: Disability Tags: Pharmaceutical Source Type: news
Conclusions: No significant difference was noted in regional cerebral oxygen saturation between patients operated on in the beach chair position and those operated on in the semi-upright sitting position. A direct relation was noted between the decrease in mean arterial pressure and decrease in cerebral oxygen saturation.
Source: Current Orthopaedic Practice - Category: Orthopaedics Tags: SPECIAL FOCUS: Resident Research Award Source Type: research
Ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) like naproxen are and have been the go-to “benign” pain medication for doctors and patients alike. Why? They aren’t addictive, and it’s not easy to overdose. Serious side effects like gastrointestinal ulcers and bleeding seemed to be limited to high doses taken for longer periods or time, or to people with significant medical problems. Even before the era of the opioid epidemic, it was raining NSAIDs, across the country. In 2004, the manufacturer of the NSAID Vioxx pulled it from the market because the drug was associated with serious...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Back Pain Drugs and Supplements Headache Health Heart Health Injuries Pain Management Source Type: blogs
More News: Abatacept | Actemra | Arthritis | Canada Health | Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Health Insurance | Heart | Heart Attack | Heart Failure | Insurance | Orencia | Rheumatoid Arthritis | Rheumatology | Rituxan | Stroke | Study